This review will focus on blinatumomab, a bi-specific anti-CD19/CD3 antibody that has shown efficacy in adult patients with precursor B-ALL (12) and is currently being evaluated in the pediatric setting. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.